CCC vs DRIO vs HIMS Stock Comparison

CCC Intelligent Solutions Holdings, DarioHealth and Hims & Hers Health Prices as of Oct 27, 2026 Peers: Industry group
1 more company in this comparison (DOCS) Create a free account to keep reading and compare up to 10 companies.
DRIO DarioHealth Corp.
$3.48 -47.5% 1M -77.9% 1Y
Market cap
$32.52M
P/E
–
Revenue (TTM)
$21.00M
Div. yield
–
Healthcare IT Technology
1 win

Head to Head

9 decided of 12

CCC Intelligent Solutions Holdings leads on 5 of the 12 questions below (CCC Intelligent Solutions Holdings 5, Hims & Hers Health 3, DarioHealth 1). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionCCCDRIOHIMSLeader
Larger companyMarket capitalisation $4.53B $32.52M $6.52B HIMS
Cheaper on earningsLower P/E, profitable companies only 104.2x -0.9x -45.6x –
Cheaper on forward earningsLower price / next fiscal year consensus EPS 16.4x — — –
Faster revenue growthRevenue growth, trailing twelve months +11.6% -22.6% +28.0% HIMS
More profitableNet margin, trailing twelve months 3.8% -169.9% -5.5% CCC
Better return on capitalReturn on invested capital 2.2% -35.5% — CCC
Less leveragedLower net debt / EBITDA 3.6x -0.6x — DRIO
Higher dividend yieldTrailing dividend yield — — — –
Better 1-year returnPrice return, last 12 months -17.2% -77.9% -42.1% CCC
Better 5-year returnAnnualised price return, 5 years -8.7%/yr -59.6%/yr +28.7%/yr HIMS
Less volatileAnnualised volatility, 1 year 55.9% 83.4% 86.7% CCC
Higher overall scoreMean of the five percentile scores vs peers 71/100 29/100 41/100 CCC

Percentile Scorecard

CCCDRIOHIMS

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisCCCDRIOHIMS
Valuation 64 #33 of 89 22 #70 of 89 35 #60 of 92
Growth 85 #13 of 81 39 #50 of 81 42 #51 of 87
Profitability 73 #21 of 76 9 #69 of 76 40 #52 of 86
Financial Health 37 #60 of 94 45 #52 of 94 20 #78 of 97
Shareholder Returns 94 #4 of 51 – 69 #18 of 56
Overall 71 29 41
  • CCC ranked among 98 companies in Vertical Software
  • DRIO ranked among 98 companies in Vertical Software
  • HIMS ranked among 102 companies in Healthcare Providers

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodCCCDRIOHIMSSPY
1 month +11.6%-47.5%-5.1% -0.2%
3 months +25.8%-54.2%-4.8% +3.9%
6 months +61.8%-53.0%+0.1% +8.2%
Year to date -3.1%-69.4%-14.0% +12.9%
1 year -17.2%-77.9%-42.1% +12.3%
3 years -28.5%-86.6%+383.2% +87.4%
3 years, per year -10.6%-48.9%+69.1% +23.3%
5 years -36.5%-98.9%+253.1% +67.9%
5 years, per year -8.7%-59.6%+28.7% +10.9%
10 years —-99.7%— +261.1%
10 years, per year —-44.7%— +13.7%

Risk

MeasureCCCDRIOHIMSSPY
Volatility, 1Y 55.9%83.4%86.7% 12.7%
Downside volatility, 1Y 56.4%89.3%79.0% 12.7%
Beta vs S&P 500, 1Y 0.850.172.78 1.00
Return / volatility, 1Y -0.31-0.93-0.49 0.97
Max drawdown, 5Y -68.4%-99.1%-78.9% -25.4%
From 52-week high -17.6%-77.9%-42.1% -1.2%
52-week high $9.35$15.75$48.23 $779.14
52-week low $4.22$3.40$14.52 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleCCCDRIOHIMS
P/E now vs peer median 104.2xmedian 40.1x -0.9xmedian 40.1x -45.6xmedian 24.6x
P/S now vs peer median 4.1xmedian 2.5x 1.5xmedian 2.5x 2.5xmedian 1.6x
EV/EBITDA now vs peer median 17.4xmedian 18.5x -1.7xmedian 18.5x -94.3xmedian 14.6x
P/FCF now vs peer median 14.7xmedian 20.1x -1.3xmedian 20.1x 78.5xmedian 21.6x
P/B now vs peer median 2.6xmedian 1.8x 0.6xmedian 1.8x 20.1xmedian 3.2x
PEG now vs peer median 2.87median 1.73 -0.02median 1.73 1.15median 0.66

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsCCCDRIOHIMS
Revenue $1.11B $21.00M $2.58B
Gross profit $817.32M $12.21M $1.76B
Operating income $176.52M -$31.83M -$154.52M
Net income $42.35M -$35.67M -$142.00M
Free cash flow $307.54M -$25.48M $83.03M
R&D $211.32M $10.45M $183.38M
EPS (diluted) $0.07 $-3.82 $-0.61
Cash & equivalents $115.86M $6.63M $609.81M
Total debt $1.30B $123.36M –
Shares (diluted) 584.92M 9.34M 231.75M
Enterprise value $4.17B -$59.60M $3.72B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricCCCDRIOHIMS
P/E 104.2x -0.9x -45.6x
P/FCF 14.7x -1.3x 78.5x
P/Operating cash flow 12.1x -1.3x 24.7x
P/S 4.1x 1.5x 2.5x
P/B 2.6x 0.6x 20.1x
P/Tangible book 5.6x 0.8x -66.0x
EV/EBITDA 17.4x -1.7x -94.3x
EV/EBIT 32.3x -1.6x -36.7x
EV/Revenue 5.1x 2.4x 2.2x
EV/FCF 18.6x -1.9x 68.4x
EV/Operating cash flow 15.3x -2.0x 21.5x
PEG (3Y EPS CAGR) 2.87 -0.02 1.15

Growth

14 metrics
MetricCCCDRIOHIMS
Revenue growth (1Y) 11.6% -22.6% 28.0%
Revenue CAGR (3Y) 10.7% -7.6% 53.7%
Gross profit growth (1Y) 9.3% -18.2% 15.0%
Gross profit CAGR (3Y) 11.4% 7.7% 45.7%
Operating income growth (1Y) 177.7% 24.8% -223.0%
Operating income CAGR (3Y) 94.3% 14.0% -43.7%
Net income growth (1Y) 614.1% 19.3% -173.3%
Net income CAGR (3Y) 35.8% 14.8% -44.6%
EPS growth (1Y) 2,387% 83.9% -181.3%
EPS CAGR (3Y) 36.3% 54.6% -39.6%
Operating cash flow growth (1Y) 34.0% 5.4% 0.7%
Operating cash flow CAGR (3Y) 20.2% 8.4% 117.6%
Free cash flow growth (1Y) 36.0% 5.3% -37.3%
Free cash flow CAGR (3Y) 23.5% 8.7% 67.0%

Profitability

14 metrics
MetricCCCDRIOHIMS
Gross margin 73.5% 58.2% 68.4%
EBITDA margin 29.6% -141.5% -2.3%
Operating margin 15.9% -151.6% -6.0%
Pretax margin 9.9% -167.6% -6.3%
Net margin 3.8% -169.9% -5.5%
FCF margin 27.7% -121.3% 3.2%
Operating cash flow margin 33.5% -120.7% 10.2%
Return on equity 2.4% -60.7% -36.9%
Return on assets 1.2% -35.7% -4.8%
Return on invested capital 2.2% -35.5% –
Return on capital employed 5.4% -35.2% -10.5%
Asset turnover 0.3x 0.2x 0.9x
Cash conversion (OCF / net income) 8.8x 0.7x -1.9x
Stock comp / revenue 11.7% 33.6% 6.0%

Financial Health

11 metrics
MetricCCCDRIOHIMS
Debt / assets 36.8% 32.2% –
Debt / equity 0.7x 0.6x –
Net debt / EBITDA 3.6x -0.6x –
Debt / FCF 4.2x -1.2x –
Liabilities / assets 49.8% 43.0% 91.1%
Equity / assets 50.2% 57.0% 8.9%
Interest coverage 2.3x -7.0x –
Current ratio 1.6x 2.3x 0.9x
Quick ratio 1.2x 1.6x 0.8x
Cash ratio 0.5x 1.5x 0.6x
Altman Z-score 1.37 -7.03 1.61

Shareholder Returns

7 metrics
MetricCCCDRIOHIMS
Dividend yield – – –
Net buyback yield 11.4% – 1.0%
Shareholder yield 11.4% – 1.0%
Payout ratio (earnings) – – –
Payout ratio (FCF) – – –
Dividend growth (1Y) – – –
Dividend CAGR (3Y) – – –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusCCCDRIOHIMS
Forward P/E 16.4xFY2026 – –
EPS, next fiscal year $0.47FY2026 $-3.84FY2026 $-0.62FY2026
EPS growth, next FY +30.6%FY2026 – -221.6%FY2026
EPS growth, the year after +6.4% – –
Revenue, next fiscal year $1.13BFY2026 $23.11MFY2026 $3.34BFY2026
Revenue growth, next FY +6.7%FY2026 +3.3%FY2026 +42.0%FY2026
Revenue growth, the year after +14.2% +25.1% +28.1%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersCCCDRIOHIMS
Held by institutions 100.0% – 66.8%
Institutions holding 353 – 508
Change in shares held, QoQ +2.6% – +4.5%
Institutions buying 161 – 324
Institutions selling 160 – 129
Buyers to sellers 1.01 – 2.51

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

CCCDRIOHIMS
CCC 1.00 -0.01 0.21
DRIO -0.01 1.00 -0.04
HIMS 0.21 -0.04 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, CCC, DRIO and HIMS?

Hims & Hers Health (HIMS) is the largest by market capitalisation: CCC Intelligent Solutions Holdings (CCC) $4.53B, DarioHealth (DRIO) $32.52M, Hims & Hers Health (HIMS) $6.52B.

Which company is growing faster?

Hims & Hers Health (HIMS) grew revenue fastest over the trailing twelve months: CCC Intelligent Solutions Holdings (CCC) +11.6%, DarioHealth (DRIO) -22.6%, Hims & Hers Health (HIMS) +28.0%.

Which company is more profitable?

CCC Intelligent Solutions Holdings (CCC) has the highest net margin (CCC Intelligent Solutions Holdings (CCC) 3.8%, DarioHealth (DRIO) -169.9%, Hims & Hers Health (HIMS) -5.5%). On return on invested capital, CCC Intelligent Solutions Holdings (CCC) leads (CCC Intelligent Solutions Holdings (CCC) 2.2%, DarioHealth (DRIO) -35.5%).

Which stock has performed better?

Over the past year CCC Intelligent Solutions Holdings (CCC) returned the most: CCC Intelligent Solutions Holdings (CCC) -17.2%, DarioHealth (DRIO) -77.9%, Hims & Hers Health (HIMS) -42.1%. Over five years, Hims & Hers Health (HIMS) compounded fastest (CCC Intelligent Solutions Holdings (CCC) -8.7%/yr, DarioHealth (DRIO) -59.6%/yr, Hims & Hers Health (HIMS) +28.7%/yr). Returns are price only, before dividends.

Which stock is riskier?

By one-year price volatility, CCC Intelligent Solutions Holdings (CCC) has been the steadiest (CCC Intelligent Solutions Holdings (CCC) 55.9%, DarioHealth (DRIO) 83.4%, Hims & Hers Health (HIMS) 86.7%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, CCC, DRIO and HIMS?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, CCC Intelligent Solutions Holdings (CCC) leads on 5. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.